Retinoid replacements and opsin agonists and methods for the use thereof
Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.
1. A method for the treatment of Leber Congenital Amaurosis in a human eye, the method comprising:
administering to a human subject an effective amount of 9-cis-retinal, wherein the 9-cis retinal is administered by intraocular or periocular injection.
2. The method according to claim 1 , wherein the 9-cis-retinal is injected into a vitreous of the eye.
3. The method according to claim 1 , wherein said administering reduces or slows vision loss.
4. The method according to claim 1 , wherein said administering restores or stabilizes photoreceptor function.
5. The method according to claim 1 , wherein the 9-cis retinal is administered at a dose of about 0.1 mg to about 90 mg.
6. A method of restoring photoreceptor function in a human eye having an endogenous 11-cis-retinal deficiency that is Leber Congenital Amaurosis, the method comprising:
administering to a human subject an effective amount of 9-cis-retinal, wherein the 9-cis retinal is administered by intraocular or periocular injection.
7. The method according to claim 6 , wherein the 9-cis-retinal is injected into a vitreous of the eye.
8. The method according to claim 6 , wherein the method of restoring photoreceptor function reduces or slows vision loss.
9. The method according to claim 6 , wherein the 9-cis retinal is administered at a dose of about 0.1 mg to about 90 mg.
10. A method of administering a synthetic retinoid that is 9-cis-retinal to a human subject having Leber Congenital Amaurosis, comprising:
administering by intraocular or periocular injection to a human eye an effective amount of 9-cis-retinal, whereby the 9-cis retinal binds to opsin in the human eye and forms a functional opsin/9-cis-retinal complex.
11. The method according to claim 10 , wherein the 9-cis-retinal is injected into a vitreous of the eye.
12. The method according to claim 10 , wherein said administering reduces or slows vision loss in the human subject.
13. The method according to claim 10 , wherein the 9-cis retinal is administered at a dose of about 0.1 mg to about 90 mg.